Literature DB >> 15046232

Pancreatic pseudotumor with sclerosing pancreato-cholangitis: is this a systemic disease?

Mohssen Nassiri Toosi1, Jenny Heathcote.   

Abstract

OBJECTIVE AND
METHOD: Primary sclerosing cholangitis (PSC) is a disease that predominantly affects the biliary tree, although the pancreas may also be affected. A review of the presenting features of all patients given a diagnosis of PSC at a single center was conducted. The aim was to clarify the presentation of patients with pseudotumor of the pancreas in this patient population.
RESULTS: Seventy-two patients were diagnosed with PSC either by ERCP (63/72 = 88%) or by liver biopsy (9/72 = 12%). The diagnosis of PSC was made following referral for abnormal liver tests (67%), jaundice (17%), and acute cholangitis (5%). Inflammatory bowel disease (IBD) (60%), non-insulin-dependent diabetes mellitus (NIDDM) (13%), thyroid disease (8%), and pancreatic disease (7%) were the major coexistent extrahepatic diseases. Three patients, all with marked weight loss, who presented with jaundice, abdominal pain, and/or diarrhea were found to have a pancreatic mass at first presentation. Clinical and radiological findings suggested pancreatic malignancy, and only later was advanced sclerosing cholangitis identified. The biopsy of the pancreas in two of these three patients revealed chronic pancreatitis. The long-term follow-up and good clinical response to medical therapy confirmed lack of pancreatic malignancy. These three patients all had other evidence of systemic involvement: submandibular gland fibrosis and urethral stricture in one, fibromuscular dysplasia of the renal artery in another, and retroperitoneal fibrosis in the third. None had IBD.
CONCLUSION: Pancreatic pseudotumor with sclerosing pancreato-cholangitis may be a manifestation of a systemic disease characterized by nonmalignant strictures and multifocal fibroinflammatory processes, unlike classical PSC.

Entities:  

Mesh:

Year:  2004        PMID: 15046232     DOI: 10.1111/j.1572-0241.2004.04075.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

2.  Diagnostic and treatment modalities for autoimmune pancreatitis.

Authors:  Atul S Rao; Francesco Palazzo; Joanne Chung; Eric Hager; Hamid Abdollahi; Charles J Yeo
Journal:  Curr Treat Options Gastroenterol       Date:  2006-09

3.  Response to steroid therapy of sclerosing cholangitis after duodenopancreatectomy due to autoimmune pancreatitis.

Authors:  D Padilla; T Cubo; P Villarejo; R Pardo; A Jara; R de la Plaza; J Hernández
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 4.  Primary sclerosing cholangitis--approach to diagnosis.

Authors:  Ian L Steele; Cynthia Levy; Keith D Lindor
Journal:  MedGenMed       Date:  2007-04-25

Review 5.  Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease.

Authors:  Terumi Kamisawa; Atsutake Okamoto
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

6.  Progressive tumefactive fibroinflammatory lesion of the infratemporal fossa treated by radiation therapy.

Authors:  Frank J P Hoebers; Bayardo Perez Ordonez; Jon Irish; Rand E Simpson; Eugene Yu; Brian O'Sullivan
Journal:  Rare Tumors       Date:  2012-03-09

Review 7.  Hyper-IgG4 disease: report and characterisation of a new disease.

Authors:  Guy H Neild; Manuel Rodriguez-Justo; Catherine Wall; John O Connolly
Journal:  BMC Med       Date:  2006-10-06       Impact factor: 8.775

8.  Post-surgical Pancreatitis Masquerading as Recurrent Neuroendocrine Cancer.

Authors:  Anya Adair; Anca Oniscu; Stephen J Wigmore
Journal:  J Surg Case Rep       Date:  2010-06-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.